The risk of serious adverse events was similar in participants assigned to treatment and to control. These data are supported by post hoc analyses of randomized trials of statin vs. placebo that focus on the subset of participants with CKD at baseline. In general, these analyses suggest that statins reduce the RR of cardiovascular events to a similar extent among patients with and without CKD but that the absolute benefit of treatment is larger in the former due to their higher baseline risk.34 In addition, the risk of adverse events associated with statin treatment appeared similar in participants with and without CKD. However, most of the participants with CKD in these analyses and very few had eGFR . Since the absolute risk in people who are non-dialysis- aged Z50 years is consistently greater than 10 per 1000 patient-years, in the judgment of the Work Group, knowledge of LDL-C is not required to gauge average coronary risk in this population. Although multivariable prediction instruments might yield more precise estimates of risk for individuals, the Work Group judged that the increased simplicity of an age-based approach was defensible for patients aged Z50 years based on the data presented above and would enhance uptake of the guideline. There is no evidence that ezetimibe monotherapy will improve clinically relevant outcomes in patients with or without CKD. Therefore, ezetimibe monotherapy is not recommended. The combination of findings from SHARP, post hoc analyses of randomized trials from the general population (focusing on the subset with CKD), and the large body of evidence from the general population trials collectively provide a strong rationale for this recommendation. In the judgment of the Work Group, these data warrant a strong recommendation. 